Clinical Trials Logo
  1. Home
  2. Drug Addiction
  3. NCT02902081

Cannabidiol and Emotional Stimuli — CAS  

Drug Addiction Clinical Trial

Official title:
Effects of Cannabidiol on Responses to Emotional Stimuli

Clinical Trial Summary

The purpose of this research is to examine the effect of cannabidiol (CBD), a cannabinoid compound found in marijuana, on responses to emotional stimuli. Both preclinical and clinical studies indicate that CBD may act to reduce anxiety without excessive sedative side-effects. Thus the investigators hypothesize that CBD may reduce responses specifically to negative emotional and social stimuli, including pictures and emotional faces, without altering responses to positive stimuli. To examine this, the investigators will administer placebo, 300mg, 600mg, and 900mg CBD to healthy normal adults in a double-blind within-subjects study. The investigators will measure subjective and subtle physical responses to positive and negative stimuli using measures that have been characterized with classic anxiety-reducing drugs and drugs of abuse. Further, the investigators will examine whether CBD-induced changes in these measures of emotional response relate to changes in actual behavior in a controlled social interaction. These results will allow the investigators to examine the potential usefulness of CBD as an anxiety-reducing drug, and suggest mechanisms by which CBD may reduce anxiety.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02902081
Study type Interventional
Source University of Chicago
Contact
Status Completed
Phase N/A
Start date February 2013
Completion date March 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Completed NCT02939352 - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues Early Phase 1
Completed NCT02437123 - The Cedar Project: Impact of mHealth for HIV Prevention Among Young Indigenous People Who Use Illicit Drugs N/A
Completed NCT02192931 - A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users Phase 4
Completed NCT02224508 - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks N/A
Completed NCT01685073 - The Role of Sleep in the Treatment of Cannabis Use Disorders Phase 2/Phase 3
Completed NCT01591239 - Home-Based Program to Help Parents of Drug Abusing Adolescents N/A
Completed NCT00317460 - Buprenorphine and Integrated HIV Care Phase 4
Completed NCT03678051 - CBT4CBT for Women in Residential Treatment for Substance Use Disorders N/A
Completed NCT04105621 - Westlake Personalized Nutrition and Health Cohort for Drug Addicts
Withdrawn NCT05440721 - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification N/A
Completed NCT03694327 - Innovative Digital Therapeutic for Smoking Cessation N/A
Completed NCT00390559 - Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3 N/A
Completed NCT00244699 - Integrating Mindfulness-Based Skills Training Into Brief Outpatient Treatment for Substance Abusing Youth N/A
Completed NCT00496990 - Treating the Partners of Drug Using Pregnant Women: Stage II Phase 2/Phase 3
Completed NCT03411265 - RETAIN: Retaining Opioid Users Entering Medication Assisted Treatment and Encouraging HCV/HIV Testing N/A
Completed NCT03402672 - AWAITS: A Web-based E-health Application for Active Illicit Opioid Users N/A
Completed NCT01003496 - Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial Phase 3
Completed NCT02091284 - Bilateral Prefrontal Modulation in Alcoholism N/A
Completed NCT02091167 - Bilateral Prefrontal Modulation in Crack-cocaine Addiction Phase 2